Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vicriviroc in treatment-naive adults with CCR5-tropic HIV infection
2007-003133-16Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of vicriviroc in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Merck & Co. Primary endpoint: Mean change from baseline in log10 HIV RNA at Week 48. Started Nov 2007; status: terminated.
02
Drugs
vicriviroc
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2007-003133-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003133-16.